| Sunday, January 11 |
|
3:00 - 7:30 PM
|
Registration
|
Ballroom Lobby
|
|
6:30 - 7:30 PM
|
Refreshments
|
Ballroom Lobby
|
|
7:30 - 9:30 PM
|
Keynote Session
|
Ballroom 2-3
|
|
Irving L. Weissman,
Stanford University
Normal and Neoplastic Stem Cell
|
|
|
|
|
|
Stephen S. Hall,
"More Commotion in the Blood:" A Science Writer's View from the Sidelines
|
|
| Monday, January 12 |
|
7:00 - 8:00 AM
|
Breakfast
|
Golden Cliff / Eagles
|
|
8:00 - 11:00 AM
|
Tumor Surveillance and Microenvironment
|
Ballroom 2-3
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Ballroom Lobby
|
|
11:00 AM -
|
On Own for Lunch
|
|
|
11:00 AM - 1:00 PM
|
Poster Setup
|
Superior / Superior Lobby / Wasatch / Maybird
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Superior / Superior Lobby / Wasatch / Maybird
|
|
2:30 - 4:30 PM
|
Workshop 1: Events in the Microenvironment
|
Ballroom 2
|
|
*
Victor H. Engelhard,
University of Virginia
|
|
|
Andrew R. Ferguson,
University of Virginia
Differential Homing Receptor Expression on T Cells Activated In Distinct Lymphoid Organs Resulting in T Cell Migration to Tumors
|
|
|
Michelle Li Wen Hong,
Biomedical Sciences Institute
The Role of the Immune System in the Control of Cancer in a Spontaneous Mouse Melanoma Model
|
|
|
Jennifer Landsberg,
Klinik und Poliklinik für Dermatologie und Allergologie
Primary Cutaneous Melanomas in HGFxCdk4R24C Mice Avoid Recognition and Destruction by the Cellular Immune System
|
|
|
Jacqueline D. Shields,
Ecole Polytechnique Federale de Lausanne
Lymph Node Mimicry by Tumors Induces Immunological Tolerance in a Complement-Dependent Manner
|
|
|
Elizabeth D. Thompson,
University of Virginia
Tumors can Serve as a Primary Site of Naïve T Cell Activation
|
|
|
Roberta Faccio,
Washington University
Important Contribution of the Immune System in Regulating the Tumor/Bone Vicious Cycle Independent from Osteoclasts
|
|
|
2:30 - 4:30 PM
|
Workshop 2: Tolerance and Regulatory Checkpoints
|
Ballroom 3
|
|
*
Dario A.A. Vignali,
St. Jude Children's Research Hospital
|
|
|
Marieke F. Fransen,
Leiden University Medical Center
Low Dose Anti-CD40 Activating Therapy in the Tumor-Draining Area is as Effective in Generating an Anti-Tumor CTL Response as a High Dose Systemic Therapy, with Decreased Toxicity
|
|
|
Lukas Kremmler,
Netherlands Cancer Institute
The Role of PD-1 on MTOC Localization during the “Kiss of Death”
|
|
|
Amanda L. Sherwood,
University of Western Australia
Dual Control of Anti-Tumor CD8 and Tumor-Promoting CD4 T Cells through the PD-1/PD-L1 Pathway
|
|
|
|
|
|
Jaikumar Duraiswamy,
Emory University School of Medicine
Programmed Death-1 Localization at the Immune Synapse is Different in Exhausted Versus Effector LCMV Specific T Cells
|
|
|
Andreas Bonertz,
German Cancer Research Center
Regulatory T Cells Exhibit Highly Diverse Recognition Patterns of Tumor Antigens and Their Depletion Boosts the Reactivity of Tumor-Specific T Cells in Colorectal Carcinoma Patients
|
|
|
Joseph F. Grosso,
Johns Hopkins School of Medicine
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Tolerized CD8 T Cells
|
|
|
2:30 - 4:30 PM
|
Workshop 3: gammadelta and NK Cells
|
Ballroom 1
|
|
*
Jean-Jacques Fournié,
INSERM U563
Catch, Kiss and Kill: Gamma Delta T Cell-Based Cancer Immunotherapies
|
|
|
Massimo Massaia,
Universita' degli Studi di Torino
Accumulation of Terminally Differentiated Effector Vgamma9/Vdelta2 T Cells in Patients with Chronic Lymphocytic Leukemia: a Novel Mechanism of Immunoediting Driven by the Mevalonate Pathway of Tumor Cells
|
|
|
Volker Kunzmann,
Medizinische Klinik und Poliklinik II
gamma delta T Cell-Mediated Immunotherapy for Cancer: Current Reality and Future Options
|
|
|
Julie Dechanet-Merville,
Université Bordeaux 2
Protection from Cancer After Kidney Transplantation is Correlated with Cytomegalovirus-Induced gamma delta T Cells
|
|
|
Hollie J. Pegram,
Peter MacCallum Cancer Centre
Gene Modified Natural Killer Cells for Cancer Immunotherapy
|
|
|
Nourredine Himoudi,
Institute of Child Health and Great Ormond Street Hospital
The Bone Marrow Derived Interferon Producing Killer Dendritic Cells (IKDC) Subset of Cells Account for the Tumoricidal Activity of Unpulsed Dendritic Cells by Migrating into Tumors and Cross Presenting Antigens in vitro and in vivo
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Ballroom Lobby
|
|
5:00 - 7:00 PM
|
Homing to Tumor Sites - You Can't Always Get Where You Want
|
Ballroom 2-3
|
|
Owen N. Witte,
University of California, Los Angeles
Tracking Responses – It’s Nice Having a PET (Scanner)
|
|
|
Rachael A. Clark,
Brigham and Women's Hospital
Short Talk: Imiquimod Enhances IFNgamma Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin
|
|
|
|
|
|
|
|
|
*
Thomas F. Gajewski,
University of Chicago
T Cells and Tumors — An Avoidable Attraction
|
|
|
George Coukos,
University of Pennsylvania
“Seek (in the Soil) and You Shall Find”: Interrogation of the Tumor Microenvironment Reveals Critical Mechanisms Modulating Homing of T cells to Tumors
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Superior / Superior Lobby / Wasatch / Maybird
|
|
7:30 - 10:00 PM
|
Poster Session 1
|
Superior / Superior Lobby / Wasatch / Maybird
|
| Tuesday, January 13 |
|
7:00 - 8:00 AM
|
Breakfast
|
Golden Cliff / Eagles
|
|
8:00 - 11:00 AM
|
Immunologic Restraint
|
Ballroom 2-3
|
|
*
James P. Allison,
Memorial Sloan-Kettering Cancer Center
Checkpoint Blockade in Tumor Immunotherapy: New Insights and Opportunities
|
|
|
Alexander Y. Rudensky,
Memorial Sloan-Kettering Cancer Center
Cell-Mediated Control of Immune Mediated Inflammation
|
|
|
Sergio A. Quezada,
Memorial Sloan-Kettering Cancer Center
Short Talk: CTLA-4 Blockade Prevents de Novo in vivo Generation of Foxp3+ and IL10+ Regulatory T Cells and Promotes Potent Tumor Rejection Upon Transfer of Tumor-Reactive CD4+ T Cells
|
|
|
Benoît J. Van den Eynde,
University of Louvain
Fighting Tumoral Immune Resistance
|
|
|
Richard A. Flavell,
Yale University School of Medicine
Why TGF-beta May Not Be Good For You
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Ballroom Lobby
|
|
11:00 AM -
|
On Own for Lunch
|
|
|
11:00 AM - 1:00 PM
|
Poster Setup
|
Superior / Superior Lobby / Wasatch / Maybird
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Superior / Superior Lobby / Wasatch / Maybird
|
|
2:30 - 4:30 PM
|
Workshop 4: Tumor Antigens
|
Ballroom 2
|
|
*
Cornelis J. M. Melief,
Leiden University Medical Center
|
|
|
Mirjam H.M. Heemskerk,
Leiden University Medical Center
SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens
|
|
|
John J. Miles,
Queensland Institute of Medical Research
The T Cell Receptor Repertoire to Epstein-Barr Virus
|
|
|
Inge Jedema,
Leiden University Medical Center
High Avidity HLA-A2-Restricted CD8+ T Cells Against the Wilms Tumor Protein (WT1) Can Only be Isolated from HLA-A2 Negative Donors not Subjected to HLA-A2-Mediated Thymic Deletion
|
|
|
Karen Hastings,
University of Arizona College of Medicine, Phoenix
Lysosomal Thiol Reductase GILT is Important in Immune Recognition of Melanoma Antigen TRP1
|
|
|
Michel Kester,
Leiden University Medical Center
A Proteomics Approach to Identification of Antigens for T Cell Mediated Immunotherapy
|
|
|
Peter A. Savage,
University of Chicago
Repertoire Selection of Tumor-Infiltrating T Cell Populations in a Mouse Model of Spontaneous Prostate Cancer
|
|
|
2:30 - 4:30 PM
|
Workshop 5: Vaccines
|
Ballroom 3
|
|
*
Jeffrey J. Molldrem,
University of Texas MD Anderson Cancer Center
|
|
|
†,
|
|
|
†,
|
|
|
†,
|
|
|
†,
|
|
|
Alice Yewdall,
New York University
Peptide-Loaded Dendritic Cell Vaccines Require Endogenous Antigen Presenting Cells for Maximal Naïve CD8+ T Cell Activation
|
|
|
Kimberly R. Jordan,
University of Colorado Health Sciences Center
Protective Mimotope Vaccines Elicit a Less Diverse Repertoire of T Cells that Produces IFN-gamma and have Higher Affinity for TAA
|
|
|
|
|
|
Lisa M. McEwen,
University of Georgia
Mechanistic Study of the DOTAP/E7 Therapeutic Vaccine
|
|
|
Hideho Okada,
University of Pittsburgh
Induction of Type-1 CTL Responses Against Novel Glioma-Associated Antigen -Derived Epitopes Epha2 (883-891) and IL-13Ralpha2 (345-353)
|
|
|
2:30 - 4:30 PM
|
Workshop 6: Macrophages/Inflammation/Tumor Promotion
|
Ballroom 1
|
|
*
Suzanne Ostrand-Rosenberg,
University of Maryland
Myeloid -Derived Suppressor Cells Inhibit T Cell Activation and Anti-Tumor Immunity by Sequestering Cystine and Cysteine
|
|
|
Marta Coscia,
Università di Torino
Clinically Relevant Doses of Zoledronic Acid Efficiently Target Tumor Associated Macrophages and Cancer Microenvironment Prolonging Disease-Free and Overall Survival in a Transgenic Model of Human Breast Cancer
|
|
|
Matthew R. Porembka,
Washington University in St. Louis
Zoledronate Impairs Intratumoral Accumulation of Myeloid Derived Suppressor Cells Resulting in Smaller Tumors and Prolonged Survival
|
|
|
Brent H. Koehn,
La Jolla Institute for Allergy & Immunology
Tolerogenic Programming of CD8 T Cells by B Cell APC
|
|
|
George C. Prendergast,
Lankenau Institute for Medical Research
IDO Pathway in Cancer and Immune Escape
|
|
|
Ainhoa Perez-Diez,
NIAID, National Institutes of Health
Tumor Specific CD4 Cells, but not CD8 Cells, Induce Phenotypic and Functional Changes on Tumor Associated Macrophages
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Ballroom Lobby
|
|
5:00 - 7:00 PM
|
Innate Conditioning: 'Finis Origine Pendet'
|
Ballroom 2-3
|
|
|
|
|
Giorgio Trinchieri,
National Cancer Institute at Frederick
Innate Resistance, Inflammation, and Cancer
|
|
|
*
Kenneth M. Murphy,
Washington University School of Medicine
Transcriptional Regulation of Dendritic Cell Subsets for Cross-Presentation and Tumor Rejection
|
|
|
Federica Sallusto,
Institute for Research in Biomedicine
Chemokine Receptors - Getting You Where You Need to Go
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Superior / Superior Lobby / Wasatch / Maybird
|
|
7:30 - 10:00 PM
|
Poster Session 2
|
Superior / Superior Lobby / Wasatch / Maybird
|
| Wednesday, January 14 |
|
7:00 - 8:00 AM
|
Breakfast
|
Golden Cliff / Eagles
|
|
8:00 - 11:00 AM
|
Tumor Antigens: A Turn-On or a Turn-Off?
|
Ballroom 2-3
|
|
Bruce W. Robinson,
University of Western Australia
Chemotherapy as a Strategy to Induce Antigen Presentation
|
|
|
Mark J. Smyth,
Peter MacCallum Cancer Centre
Combination Chemo-Immunotherapies: Looking for Synergy
|
|
|
Mark P. Chao,
Stanford University
Short Talk: CD47 Regulates a Mechanism of Immune Evasion in Acute Myeloid Leukemia Stem Cells
|
|
|
*
Laurence Zitvogel,
Institut Gustave Roussy
Novel Subsets of NK Cells and Regulation during Cancer Progression: Regulatory NK Cells and DC-like NK Cells
|
|
|
Jay A. Berzofsky,
National Cancer Institute, National Institutes of Health
Role of NKT Cell Subsets in the Regulation of Anti-Tumor Immunity
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Ballroom Lobby
|
|
11:00 AM -
|
On Own for Lunch
|
|
|
11:00 AM - 1:00 PM
|
Poster Setup
|
Superior / Superior Lobby / Wasatch / Maybird
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Superior / Superior Lobby / Wasatch / Maybird
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Ballroom Lobby
|
|
5:00 - 7:00 PM
|
Adoptive T Cell Therapy
|
Ballroom 2-3
|
|
*
Philip D. Greenberg,
University of Washington
Building a T Cell Response Effective for Eradicating Tumors
|
|
|
|
|
|
Mark E. Dudley,
Health & Human Services, National Institutes of Health
Clinical Trials with Cell and Gene Therapy for Patients with Melanoma
|
|
|
Gert Riethmüller,
University of Munich
Late Breaking Short Talk: The Promise of T Cell-Engaging BiTE Antibodies for Cancer Therapy
|
|
|
Nicholas P. Restifo,
National Cancer Institute, National Institutes of Health
Enhancing the Power of Tumor-Specific T Cells
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Superior / Superior Lobby / Wasatch / Maybird
|
|
7:30 - 10:00 PM
|
Poster Session 3
|
Superior / Superior Lobby / Wasatch / Maybird
|
| Thursday, January 15 |
|
7:00 - 8:00 AM
|
Breakfast
|
Golden Cliff / Eagles
|
|
8:00 - 11:00 AM
|
Vaccines to Treat Cancer
|
Ballroom 2-3
|
|
*
Ralph M. Steinman,
Rockefeller University
Vaccination with Cancer Antigens Selectively Targeted to Dendritic Cells in situ
|
|
|
Lionel J. Apetoh,
Brigham and Women's Hospital, Harvard Medical School
Short Talk: Endogenous Danger Signals Ferried by Dying Tumor Cells to Dendritic Cells Dictate the Efficacy of Anticancer Chemotherapy and Radiotherapy
|
|
|
Nina Bhardwaj,
New York University School of Medicine
Targeting Dendritic Cells to Enhance Anti-Cancer Immunity
|
|
|
|
|
|
Padmanee Sharma,
University of Texas MD Anderson Cancer Center
Immune Responses Mediated By CTLA-4 Blockade
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Ballroom Lobby
|
|
11:00 AM -
|
On Own for Lunch
|
|
|
2:30 - 4:30 PM
|
Workshop 7: Adoptive Therapy
|
Ballroom 2
|
|
*
Stanley R. Riddell,
Fred Hutchinson Cancer Research Center
|
|
|
Salvatore Fiorenza,
Diamantina Institute for Cancer, Immunology and Metabolic Medicine
Central Memory CD8 T Cells are More Potent than Effector Memory T Cells and Show Heightened Responses to a Local Inflammatory Stimulus
|
|
|
Michele L. Martin,
University of Victoria
Identifying Tumor-Specific Determinants of T Cell Infiltration After Adoptive Immunotherapy
|
|
|
Tobias Seibel,
German Cancer Research Center
Local Low Dose Irradiation Triggers Tumor Infiltration by Adoptively Transferred and Host T Lymphocytes and Enhances Immunotherapy in Mice
|
|
|
Ingunn M. Stromness,
University of Washington
Targeting Cbl-b in Antigen-Specific CD8+ T Cells for Adoptive Immunotherapy of Progressive Leukemia in a Murine Model
|
|
|
Robbert Spaapen,
Universitair Medisch Centrum Utrecht
Minor Histocompatibility Antigen Specific CD4+ T Cells for Adoptive Immunotherapy of Multiple Myeloma in Xenografted rag2-/-ãc-/- Mice
|
|
|
Eduardo Davila,
Louisiana State University
Overexpressing TLR2-MyD88 in Tumor-specific CD8 T cells Enhances Antitumor Activity
|
|
|
2:30 - 4:30 PM
|
Workshop 8: Engineering Tumor Reactivity with TCRs/CARs
|
Ballroom 3
|
|
*
Michael Jensen,
City of Hope
|
|
|
Zelig Eshhar,
Weizmann Institute of Science
Redirected, Genetically Engineered T Cells for Adoptive Immunotherapy of Cancer
|
|
|
Gavin M. Bendle,
Netherlands Cancer Institute
TCR Gene Transfer-Induced GvHD Results in Lethal Pathology in Mice
|
|
|
Andy K. Sewell,
University of Cardiff
Enhanced TCRs for Mobilizing Cellular Immunity for Cancer Therapy
|
|
|
Cor H. J. Lamers,
Erasmus MC, Daniel den Hoed Cancer Center
Humoral and Cellular Immune Responses Towards the scFvG250 Transgene in the Rotterdam Retargeted T Cell Therapy Trial
|
|
|
Laura A. Johnson,
National Cancer Institute, National Institutes of Health
High Affinity T Cell Receptor Gene Therapy Breaks Tolerance and Elicits Autoimmunity and Cancer Regression
|
|
|
Reno Debets,
Erasmus MC-Daniel
TCR Gene Transfer: MHC Class I and II-Restricted MAGE Epitopes as Melanoma-Specific Immune Targets
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Ballroom Lobby
|
|
5:00 - 6:40 PM
|
HPV: Almost a Success Story, Lessons to be Learned
|
Ballroom 2-3
|
|
Ian H. Frazer,
University of Queensland
Preventing Cervical Cancer through Immunisation
|
|
|
*
Cornelia L. Trimble,
Johns Hopkins University School of Medicine
At Your Cervix: Immune Therapies for HPV Disease
|
|
|
Cornelis J. M. Melief,
Leiden University Medical Center
Induction of Objective Clinical Responses by Therapeutic Vaccination with Synthetic Long Peptides in Patients with High Grade HPV16-induced Premalignant Vulva Lesions
|
|
|
|
|
|
6:40 - 7:00 PM
|
Concluding Remarks
|
Ballroom 2-3
|
|
Ralph M. Steinman,
Rockefeller University
Gaining Traction on Translation
|
|
|
8:00 - 9:00 PM
|
Social Hour w/ Lite Bites
|
Ballroom 1-2
|
|
8:00 - 11:00 PM
|
Entertainment
|
Ballroom 1-2
|
| Friday, January 16 |
|
|
Departure
|
|
